News & Perspective

Oct 17, 2006

Oct 17, 2006

Baxter says cell-based H5N1 vaccine shows potential in trial

(CIDRAP News) – Low doses of a cell-based avian flu vaccine triggered a good immune response to the H5N1 avian influenza virus, according to preliminary results of a clinical trial by Baxter International of Deerfield, Ill., maker of the vaccine.

Oct 04, 2006

Oct 04, 2006

Groups call for pandemic flu vaccine 'master plan'

(CIDRAP News) – Public health and infectious disease experts today called on the United States to develop a "master plan" for development of pandemic influenza vaccines in order to translate scientific advances more rapidly into improved pandemic preparedness.

Jul 18, 2006

Jul 18, 2006

Novartis to build US cell-based flu vaccine plant

(CIDRAP News) – Novartis, the Swiss-based drug manufacturer, today announced plans to build what it says will be the first US plant to make cell-culture-based influenza vaccines.

The facility will be built in Holly Springs, N.C., at a total cost of about $600 million, the company said in a news release. It will be able to produce about 50 million doses of seasonal trivalent (three-strain) flu vaccine annually.

Jul 05, 2006

Jul 05, 2006

HHS has enough H5N1 vaccine for 4 million people

(CIDRAP News) – In an update on pandemic influenza preparedness efforts, the federal government said last week it had stockpiled enough vaccine against H5N1 avian influenza virus to inoculate about 4 million people and enough antiviral medication to treat about 6.3 million.

Jun 02, 2006

Jun 02, 2006

Flu vaccine makers get HHS funds to prepare for pandemic

Jun 20, 2007 (CIDRAP News) – Federal health officials last week announced the awarding of contracts totaling $132.5 million to help two vaccine producers get ready to start churning out vaccines in the event of a flu pandemic.

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»